Welcome to our dedicated page for Belite Bio news (Ticker: $BLTE), a resource for investors and traders seeking the latest updates and insights on Belite Bio stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Belite Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Belite Bio's position in the market.
Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical firm, announced its participation in the Benchmark’s 4th Annual Healthcare House Call Investor Conference. The event, set for May 21 and 22, 2024, will be held virtually. Belite Bio's executive management will host a fireside chat at 3:00 pm ET on May 21, 2024. The company focuses on developing novel therapeutics for degenerative retinal diseases with significant unmet medical needs.
Belite Bio (NASDAQ: BLTE) announced its Q1 2024 results and provided a corporate update. The company highlighted positive data from its Phase 2 trial of Tinlarebant in STGD1 patients, showing sustained lower atrophic lesion growth. Tinlarebant is also being evaluated in ongoing Phase 3 trials (DRAGON and PHOENIX) for STGD1 and GA, respectively. Interim data from these trials are expected in Q4 2024. Financially, Belite raised $25 million through a direct offering and reported a net loss of $7.9 million for Q1 2024, up from $6.9 million in Q1 2023. The company held $95.5 million in cash and U.S. treasury bills as of March 31, 2024.
Belite Bio, Inc. (NASDAQ: BLTE) will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference in New York on May 20, 2024. The company will host a fireside chat at 3:30 pm ET, accessible via webcast on their investor relations website.
Belite Bio, Inc. (NASDAQ: BLTE) will host a webcast on May 14, 2024, to discuss the first quarter 2024 financial results and provide a business update. The company is a clinical-stage biopharmaceutical drug development company focused on degenerative retinal diseases. The webcast will be held at 4:30 p.m. Eastern Time.
Belite Bio, Inc. (BLTE) will participate in a Key Opinion Leader Webinar to discuss Stargardt Disease and Geographic Atrophy and share insights on Tinlarebant, a novel therapeutic. The webinar, moderated by Cantor Fitzgerald, will feature Dr. Michel Michaelides, a renowned expert. Tinlarebant is a promising treatment with Fast Track, Rare Pediatric Disease, and Orphan Drug designations.
Belite Bio presented additional analysis from a Phase 2 study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting. The 24-month trial showed promising results in slowing lesion growth and stabilizing visual acuity. Genetic profiling revealed that despite severe ABCA4 variants, 42% of treated subjects did not develop atrophic retinal lesions. A novel lesion size quantification method was able to detect atrophic lesions more accurately. The drug is now being evaluated in Phase 3 trials for Stargardt Disease and Geographic Atrophy.
Belite Bio presented promising data on Tinlarebant, an oral tablet aimed at slowing disease progression in patients with retinal diseases at ARVO 2024. The Phase 2 trial showed a significant reduction in atrophic lesion growth in STGD1 patients compared to standard treatment. Enrollment for Phase 3 trials is complete, with interim data expected in Q4 2024.